

Figure 1








Figure 2



3/17

Figure 3

A



B




Figure 4




Figure 5






Figure 6



7/17

Figure 7A

FOREST Plot: Association of treatment effect with survival outcome PFS within LPS (Linear Predictor Score) subgroups



8/17

Figure 7B

FOREST Plot: Association of treatment effect with survival outcome PFS within LPS (Linear Predictor Score) subgroups





Figure 7C



G, obinutuzumab; GCB, germinal center B-cell; PFS, progression-free survival; R, rituximab

10/17

Figure 8




Figure 9






Figure 9 (continued)



Forest plot evaluating treatment effect (G vs. R) in
quartiles of CD58 gene expression

HR (95% CI)







Figure 10

Figure 11



*GOYA Foundation Medicine NGS data *DLBCL BCL2 FISH data from GOYA (BCL2 translocations identified with FISH break-apart probe [50% cut-off]):
FL prevalence from literature; prevalence in DLBCL 20%, DLBCL not strong-GCB 11%, and GCB 33%
ABC, activated B-cell; FDR, false discovery rate; FISH, fluorescence in situ hybridization; GCB, germinal center B-cell; NGS, next-generation sequencing

Figure 12




Figure 13




Figure 14 (to be continued)




Figure 14 (continued)

